257 related articles for article (PubMed ID: 18544947)
1. Candidate molecular markers for histological diagnosis of early hepatocellular carcinoma.
Sakamoto M; Mori T; Masugi Y; Effendi K; Rie I; Du W
Intervirology; 2008; 51 Suppl 1():42-5. PubMed ID: 18544947
[TBL] [Abstract][Full Text] [Related]
2. Early HCC: diagnosis and molecular markers.
Sakamoto M
J Gastroenterol; 2009; 44 Suppl 19():108-11. PubMed ID: 19148803
[TBL] [Abstract][Full Text] [Related]
3. Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma.
Tremosini S; Forner A; Boix L; Vilana R; Bianchi L; Reig M; Rimola J; Rodríguez-Lope C; Ayuso C; Solé M; Bruix J
Gut; 2012 Oct; 61(10):1481-7. PubMed ID: 22287594
[TBL] [Abstract][Full Text] [Related]
4. Utility of glypican-3 and survivin in differentiating hepatocellular carcinoma from benign and preneoplastic hepatic lesions and metastatic carcinomas in liver fine-needle aspiration biopsies.
Nassar A; Cohen C; Siddiqui MT
Diagn Cytopathol; 2009 Sep; 37(9):629-35. PubMed ID: 19405109
[TBL] [Abstract][Full Text] [Related]
5. Pathology of early hepatocellular carcinoma: conventional and molecular diagnosis.
Roskams T; Kojiro M
Semin Liver Dis; 2010 Feb; 30(1):17-25. PubMed ID: 20175030
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis of well-differentiated hepatocellular lesions: role of immunohistochemistry and other ancillary techniques.
Shafizadeh N; Kakar S
Adv Anat Pathol; 2011 Nov; 18(6):438-45. PubMed ID: 21993269
[TBL] [Abstract][Full Text] [Related]
7. Glypican-3 immunostaining significantly improves histological diagnosis of hepatocellular carcinoma.
Honsová E; Lodererová A; Franková S; Oliverius M; Trunecka P
Cas Lek Cesk; 2011; 150(1):37-40. PubMed ID: 21400962
[TBL] [Abstract][Full Text] [Related]
8. Annexin A2 as a differential diagnostic marker of hepatocellular tumors.
Longerich T; Haller MT; Mogler C; Aulmann S; Lohmann V; Schirmacher P; Brand K
Pathol Res Pract; 2011 Jan; 207(1):8-14. PubMed ID: 20971570
[TBL] [Abstract][Full Text] [Related]
9. Utility of an immunohistochemical panel consisting of glypican-3, heat-shock protein-70, and glutamine synthetase in the distinction of low-grade hepatocellular carcinoma from hepatocellular adenoma.
Lagana SM; Salomao M; Bao F; Moreira RK; Lefkowitch JH; Remotti HE
Appl Immunohistochem Mol Morphol; 2013 Mar; 21(2):170-6. PubMed ID: 22914605
[TBL] [Abstract][Full Text] [Related]
10. [Selective deposition of agrin in the microvasculature of hepatocellular carcinoma: aspects in pathogenesis and differential diagnosis].
Tátrai P
Magy Onkol; 2008 Dec; 52(4):379-83. PubMed ID: 19068466
[TBL] [Abstract][Full Text] [Related]
11. Molecular signature of early hepatocellular carcinoma.
Suriawinata A; Thung SN
Oncology; 2010 Jul; 78 Suppl 1():36-9. PubMed ID: 20616582
[TBL] [Abstract][Full Text] [Related]
12. Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas.
Wang XY; Degos F; Dubois S; Tessiore S; Allegretta M; Guttmann RD; Jothy S; Belghiti J; Bedossa P; Paradis V
Hum Pathol; 2006 Nov; 37(11):1435-41. PubMed ID: 16949914
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis of hepatocellular carcinoma: role of tumor markers and liver biopsy.
Gonzalez SA; Keeffe EB
Clin Liver Dis; 2011 May; 15(2):297-306, vii-x. PubMed ID: 21689614
[TBL] [Abstract][Full Text] [Related]
14. Liver precancerous lesions and hepatocellular carcinoma: the histology report.
Roncalli M; Terracciano L; Di Tommaso L; David E; Colombo M; ;
Dig Liver Dis; 2011 Mar; 43 Suppl 4():S361-72. PubMed ID: 21459342
[TBL] [Abstract][Full Text] [Related]
15. [Tumor markers for hepatocellular carcinoma].
Fujiyama S; Tanaka M; Maeda S; Ashihara H; Hirata R
Gan To Kagaku Ryoho; 2001 May; 28(5):723-32. PubMed ID: 11383225
[TBL] [Abstract][Full Text] [Related]
16. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules.
Libbrecht L; Severi T; Cassiman D; Vander Borght S; Pirenne J; Nevens F; Verslype C; van Pelt J; Roskams T
Am J Surg Pathol; 2006 Nov; 30(11):1405-11. PubMed ID: 17063081
[TBL] [Abstract][Full Text] [Related]
17. Glypican-3 immunocytochemistry in liver fine-needle aspirates : a novel stain to assist in the differentiation of benign and malignant liver lesions.
Kandil D; Leiman G; Allegretta M; Trotman W; Pantanowitz L; Goulart R; Evans M
Cancer; 2007 Oct; 111(5):316-22. PubMed ID: 17763368
[TBL] [Abstract][Full Text] [Related]
18. Serum markers of hepatocellular carcinoma.
Spangenberg HC; Thimme R; Blum HE
Semin Liver Dis; 2006 Nov; 26(4):385-90. PubMed ID: 17051452
[TBL] [Abstract][Full Text] [Related]
19. [The diagnostic approach to hepatocellular carcinoma].
Schacherer D; Schoelmerich J; Zuber-Jerger I
Z Gastroenterol; 2007 Oct; 45(10):1067-74. PubMed ID: 17924305
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of cyclase-associated protein 2 in multistage hepatocarcinogenesis.
Shibata R; Mori T; Du W; Chuma M; Gotoh M; Shimazu M; Ueda M; Hirohashi S; Sakamoto M
Clin Cancer Res; 2006 Sep; 12(18):5363-8. PubMed ID: 17000669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
